Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

The impact of sex on angioplasty and primary stenting for femoropopliteal occlusive disease: results of the DURABILITY II trial.

Tadros RO, Faries PL, Rocha-Singh KJ, Kim Sy, Malik RK, Ellozy SH, Marin ML, Vouyouka AG.

Ann Vasc Surg. 2014 Jan;28(1):1-9. doi: 10.1016/j.avsg.2013.05.006. Epub 2013 Nov 1.

PMID:
24189009
2.

The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).

Matsumura JS, Yamanouchi D, Goldstein JA, Pollock CW, Bosiers M, Schultz GA, Scheinert D, Rocha-Singh KJ.

J Vasc Surg. 2013 Jul;58(1):73-83.e1. doi: 10.1016/j.jvs.2012.12.066. Epub 2013 May 2.

3.

Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis.

Herten M, Torsello GB, Schönefeld E, Imm B, Osada N, Stahlhoff S.

J Vasc Surg. 2015 Feb;61(2):394-9. doi: 10.1016/j.jvs.2014.08.005. Epub 2014 Oct 11.

4.

Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial.

Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Cao AY, Jaff MR; RESILIENT Investigators.

J Endovasc Ther. 2012 Feb;19(1):1-9. doi: 10.1583/11-3627.1.

PMID:
22313193
5.

German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.

Scheinert D, Schmidt A, Zeller T, Müller-Hülsbeck S, Sixt S, Schröder H, Weiss N, Ketelsen D, Ricke J, Steiner S, Rosenfield K.

J Endovasc Ther. 2016 Jun;23(3):409-16. doi: 10.1177/1526602816644592. Epub 2016 Apr 26.

PMID:
27117972
6.

Late outcomes of balloon angioplasty and angioplasty with selective stenting for superficial femoral-popliteal disease are equivalent.

Nguyen BN, Conrad MF, Guest JM, Hackney L, Patel VI, Kwolek CJ, Cambria RP.

J Vasc Surg. 2011 Oct;54(4):1051-1057.e1. doi: 10.1016/j.jvs.2011.03.283. Epub 2011 Jun 2.

7.

Endovascular first strategy for de novo TransAtlantic Inter-Society Consensus C and D femoro-popliteal disease: mid-term outcomes from a single tertiary referral center.

Grenville JL, Tan KT, Moshonov H, Rajan DK.

Vascular. 2015 Feb;23(1):31-40. doi: 10.1177/1708538114529564. Epub 2014 Apr 2.

PMID:
24695358
8.

Primary Self-EXPANDing Nitinol Stenting vs Balloon Angioplasty With Optional Bailout Stenting for the Treatment of Infrapopliteal Artery Disease in Patients With Severe Intermittent Claudication or Critical Limb Ischemia (EXPAND Study).

Schulte KL, Pilger E, Schellong S, Tan KT, Baumann F, Langhoff R, Torsello G, Zeller T, Amendt K, Brodmann M; EXPAND Investigators.

J Endovasc Ther. 2015 Oct;22(5):690-7. doi: 10.1177/1526602815598955. Epub 2015 Aug 5.

PMID:
26245919
9.

Nitinol stent implantation in the superficial femoral artery and proximal popliteal artery: twelve-month results from the complete SE multicenter trial.

Laird JR, Jain A, Zeller T, Feldman R, Scheinert D, Popma JJ, Armstrong EJ, Jaff MR; Complete SE Investigators.

J Endovasc Ther. 2014 Apr;21(2):202-12. doi: 10.1583/13-4548R.1.

PMID:
24754279
10.

A comparison of the standard bolia technique versus subintimal recanalization plus Viabahn stent graft in the management of femoro-popliteal occlusions.

Boufi M, Dona B, Orsini B, Auquier P, Hartung O, Alimi YS.

J Vasc Surg. 2010 Nov;52(5):1211-7. doi: 10.1016/j.jvs.2010.05.107. Epub 2010 Aug 8.

11.

Selective stenting in subintimal angioplasty: analysis of primary stent outcomes.

Schmieder GC, Richardson AI, Scott EC, Stokes GK, Meier GH 3rd, Panneton JM.

J Vasc Surg. 2008 Nov;48(5):1175-80; discussion 1180-1. doi: 10.1016/j.jvs.2008.05.080. Epub 2008 Sep 7.

12.

Presentation, treatment, and outcome differences between men and women undergoing revascularization or amputation for lower extremity peripheral arterial disease.

Lo RC, Bensley RP, Dahlberg SE, Matyal R, Hamdan AD, Wyers M, Chaikof EL, Schermerhorn ML.

J Vasc Surg. 2014 Feb;59(2):409-418.e3. doi: 10.1016/j.jvs.2013.07.114. Epub 2013 Sep 29.

13.

A Comparison of Clinical Outcomes for Diabetic and Nondiabetic Patients Following Directional Atherectomy in the DEFINITIVE LE Claudicant Cohort.

Garcia LA, Jaff MR, Rocha-Singh KJ, Zeller T, Bosarge C, Kamat S, McKinsey JF.

J Endovasc Ther. 2015 Oct;22(5):701-11. doi: 10.1177/1526602815599550. Epub 2015 Aug 6.

PMID:
26250748
14.

Comparison of surgical bypass with angioplasty and stenting of superficial femoral artery disease.

Malas MB, Enwerem N, Qazi U, Brown B, Schneider EB, Reifsnyder T, Freischlag JA, Perler BA.

J Vasc Surg. 2014 Jan;59(1):129-35. doi: 10.1016/j.jvs.2013.05.100. Epub 2013 Jul 24.

15.

Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.

Ohki T, Yokoi H, Kichikawa K, Kimura T, Snyder SA, Ragheb AO, O'Leary EE, Jaff MR, Ansel GM, Dake MD.

J Endovasc Ther. 2014 Oct;21(5):644-53. doi: 10.1583/14-4753.1.

PMID:
25290792
16.

Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry.

Micari A, Cioppa A, Vadalà G, Castriota F, Liso A, Marchese A, Grattoni C, Pantaleo P, Cremonesi A, Rubino P, Biamino G.

JACC Cardiovasc Interv. 2012 Mar;5(3):331-8. doi: 10.1016/j.jcin.2011.11.010.

17.

Gender-related long-term outcome of primary femoropopliteal stent placement for peripheral artery disease.

Stavroulakis K, Donas KP, Torsello G, Osada N, Schönefeld E.

J Endovasc Ther. 2015 Feb;22(1):31-7. doi: 10.1177/1526602814564382.

PMID:
25775677
18.

Safety, clinical outcome, and fracture rate of femoropopliteal stenting using a 4F compatible delivery system.

Sarkadi H, Bérczi V, Kollár A, Kiss D, Jakabfi P, Végh EM, Nemes B, Merkely B, Hüttl K, Dósa E.

Eur J Vasc Endovasc Surg. 2015 Feb;49(2):199-204. doi: 10.1016/j.ejvs.2014.12.004. Epub 2015 Jan 8.

19.

Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.

Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, Beschorner U, Schwarzwälder U, Schwarz T, Noory E.

J Endovasc Ther. 2014 Jun;21(3):359-68. doi: 10.1583/13-4630MR.1.

PMID:
24915582
20.

2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry.

Micari A, Cioppa A, Vadalà G, Castriota F, Liso A, Marchese A, Grattoni C, Pantaleo P, Cremonesi A, Rubino P, Biamino G.

JACC Cardiovasc Interv. 2013 Mar;6(3):282-9. doi: 10.1016/j.jcin.2013.01.128.

Supplemental Content

Support Center